The arrival of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable buzz within the medical community. This groundbreaking dual GIP and GLP-1 receptor medication suggests to offer notable improvements in body shedding compared to current therapies. Preliminary research trials have shown marked decreases in body fat percentage, potential